Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alnylam Pharma ( (ALNY) ) has provided an update.
On September 8, 2025, Alnylam Pharmaceuticals announced a proposed private offering of $500 million in convertible senior notes due 2028, targeting qualified institutional buyers. The offering aims to support capped call transactions and repurchase existing notes, potentially impacting Alnylam’s stock market activity and conversion price. The company plans to use the proceeds for these financial strategies and general corporate purposes, with implications for its market positioning and stakeholder interests.
The most recent analyst rating on (ALNY) stock is a Buy with a $470.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
Alnylam Pharma’s overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
Alnylam Pharmaceuticals, Inc., based in Cambridge, MA, is a leading company in the RNA interference (RNAi) therapeutics industry. It focuses on developing innovative medicines for rare and prevalent diseases with unmet needs, leveraging Nobel Prize-winning science. Alnylam’s commercial products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, while it collaborates with Novartis and Sanofi for Leqvio and Qfitlia, respectively. The company is committed to its ‘Alnylam P5x25’ strategy, aiming to deliver transformative medicines globally.
Average Trading Volume: 1,095,210
Technical Sentiment Signal: Buy
Current Market Cap: $59.64B
Find detailed analytics on ALNY stock on TipRanks’ Stock Analysis page.